Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy
  • Adenocarcinoma of Lung
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Large Cell / drug therapy
  • Carcinoma, Large Cell / genetics*
  • Carcinoma, Large Cell / pathology
  • Carcinoma, Large Cell / radiotherapy
  • Carcinoma, Neuroendocrine / drug therapy
  • Carcinoma, Neuroendocrine / genetics*
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / radiotherapy
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Exons
  • Gemcitabine
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Quinazolines / therapeutic use
  • Treatment Failure
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use
  • Vinorelbine

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Deoxycytidine
  • Vinblastine
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors
  • Cisplatin
  • Vinorelbine
  • Gemcitabine